Evaluation of NuvastaticTM in Reducing Cancer-Related Fatigue in Stage IV Colon Cancer Patients Undergoing First-Line Chemotherapy

Exclusion Criteria

• •1. Patients who have any untreated reversible medical condition which may cause fatigue (e.g. metabolic disturbance, infection, endocrine abnormalities) as per the Investigator's clinical judgment.
• •2. Patients who have stage IV Disease
• •3. Patients who have received concurrent stimulant medication (e.g. dextroamphetamine or methylphenidate) during the screening period or any medication which may interfere with study drug.
• •4. Prior metastatic chemo, targeted/immunotherapy, severe comorbidities
• •5. Female patients who are pregnant or breast-feeding.
• •6. Patients with known hepatitis C virus, hepatitis B virus, HIV infection.
• •7. Patients who have nausea and vomiting or any gastrointestinal disorder that is severe enough to interfere with study drug absorption in the opinion of the Investigator.
• •9. Patients with planned therapy or treatment with another investigational agent.
• •10. Previous exposure to any investigational agent within 4 weeks prior to screening, or planned administration of an Investigational agent, other than as specified by this protocol, during the study period.